FDA Releases Draft Guidance for Industry on Investigational New Drug Applications

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document to help sponsor-investigators prepare and submit complete Investigational New Drug Applications (INDs) to the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).